-
September 02, 2010
Pfizer has hit the acquisition trail again and is buying FoldRx Pharmaceuticals, in a move that will boost its presence in orphan and rare disease markets
-
September 02, 2010
Allergan is the latest company to settle claims of marketing products for non-approved use, securing an agreement over its wrinkle smoother Botox
-
September 02, 2010
Merck & Co and partner Cardiome have been granted marketing approval by European regulators for the intravenous formulation of their anti-arrhythmic Brinavess
-
September 02, 2010
Nycomed has begun the global market launch of its new chronic obstructive pulmonary disease Daxas, starting off in Germany
-
September 01, 2010
Genzyme Corp's chief executive has told Reuters that he is willing to sell the US biotech major to Sanofi-Aventis, but not for the $69 per share offered by the French drugmaker
-
September 01, 2010
The chances of AstraZeneca's new infant lung drug motavizumab making it to the market have taken another hit after regulators asked yet again for more data
-
September 01, 2010
Servier's Valdoxan is more efficacious than both conventional SSRI and SNRI antidepressants, according to new data presented in Amsterdam
-
September 01, 2010
Sales of drugs to treat chronic obstructive pulmonary disease (COPD) in seven major markets will grow 4.6% a year to reach more than $13 billion in 2019, says a new study.
-
September 01, 2010
Russia's Pharmsynthez has unveiled plans to float on the Moscow Interbank Currency Exchange to help fund a new facility and international expansion
-
August 31, 2010
Things are set to get hostile after Genzyme Corp unanimously rejected a $18.50 billion takeover bid from Sanofi-Aventis, raising the likelihood of a hostile offer from the French drugmaker